Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, December 13, 2016 ) This report provides comprehensive information on the therapeutic development for Pertussis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pertussis and special features on late-stage and discontinued projects.
Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
For more information about this report at http://www.reportsweb.com/pertussis-pipeline-review-h1-2015
Scope
- The report provides a snapshot of the global therapeutic landscape of Pertussis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Pertussis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Pertussis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Pertussis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001170070/sample
Reasons to Buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Pertussis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Pertussis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Companies profiles
Beijing Minhai Biotechnology Co., Ltd Beijing Tiantan Biological Products Co., Ltd. Bharat Biotech International Limited Biological E. Limited Daiichi Sankyo Company, Limited DBV Technologies S.A. Green Cross Corporation Indian Immunologicals Limited LG Life Sciences, Ltd. NanoBio Corporation Novartis AG Panacea Biotec Limited Sanofi Sanofi Pasteur SA Serum Institute of India Limited Sinovac Biotech Ltd. Synthetic Biologics, Inc. Takeda Pharmaceutical Company Limited Zydus Cadila Healthcare Limited
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001170070/discount
List of Figures
Number of Products under Development for Pertussis, H1 2015 11 Number of Products under Development for Pertussis-Comparative Analysis, H1 2015 12 Number of Products under Development by Companies, H1 2015 13 Number of Products under Investigation by Universities/Institutes, H1 2015 16 Comparative Analysis by Late Stage Development, H1 2015 17 Comparative Analysis by Clinical Stage Development, H1 2015 18 Comparative Analysis by Early Stage Products, H1 2015 19 Assessment by Monotherapy Products, H1 2015 43 Assessment by Combination Products, H1 2015 44 Number of Products by Top 10 Targets, H1 2015 45 Number of Products by Stage and Top 10 Targets, H1 2015 46 Number of Products by Top 10 Routes of Administration, H1 2015 47 Number of Products by Stage and Top 10 Routes of Administration, H1 2015 48 Number of Products by Top 10 Molecule Types, H1 2015 49 Number of Products by Stage and Top 10 Molecule Types, H1 2015 50
Purchase Complete Report at http://www.reportsweb.com/buy&RW0001170070/buy/2000
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com
Source: EmailWire.com
|
|
|
|